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Glucokinase acts as the pancreatic glucose sensor and plays a
critical role in the regulation of insulin secretion by the β-cell.
Heterozygous mutations in the glucokinase-encoding GCK gene,
which result in a reduction of the enzymatic activity, cause the
monogenic form of diabetes, MODY2 (maturity-onset diabetes of
the young 2). We have identified and functionally characterized
missense mutations in the GCK gene in diabetic families that res-
ult in protein mutations Leu165 → Phe, Glu265 → Lys and Thr206 →
Met. The first two are novel GCK mutations that co-segregate
with the diabetes phenotype in their respective families and are
not found in more than 50 healthy control individuals. In order
to measure the biochemical effects of these missense mutations
on glucokinase activity, we bacterially expressed and affinity-
purified islet human glucokinase proteins carrying the respective
mutations and fused to GST (glutathione S-transferase). En-
zymatic assays on the recombinant proteins revealed that muta-
tions Thr206 → Met and Leu165 → Phe strongly affect the kinetic
parameters of glucokinase, in agreement with the localization of
both residues close to the active site of the enzyme. In contrast,
mutation Glu265 → Lys, which has a weaker effect on the kinetics
of glucokinase, strongly affects the protein stability, suggesting
a possible structural defect of this mutant protein. Finally, none
of the mutations tested appears to affect the interaction of gluco-
kinase with the glucokinase regulatory protein in the yeast two-
hybrid system.
Key words: diabetes mellitus, enzyme kinetics, GCK gene,
glucokinase, inactivating mutation, maturity-onset diabetes of the
young (MODY).
INTRODUCTION
GK (glucokinase) (ATP:D-glucose-6-phosphotransferase; EC
2.7.1.2), also known as hexokinase D or hexokinase IV, is
one of the four glucose-phosphorylating isoenzymes present
in vertebrates. This metabolic enzyme is highly expressed in
pancreatic β-cells, hepatocytes and brain, and it catalyses the first
reaction of glycolysis by converting glucose into G6P (glucose
6-phosphate), with Mg-ATP as a second substrate. This reaction is
the first rate-limiting step in glucose metabolism that is necessary
for insulin release in the β-cell. GK plays a key role as a pancreatic
β-cell glucose sensor by integrating blood glucose levels and
glucose metabolism with insulin secretion [1,2]. This specific
function of GK is based on the particular kinetic characteristics
of this enzyme as compared with the other hexokinase isoforms,
which include a low affinity for glucose (S0.5 7–9 mmol/l), a co-
operativity with this substrate (Hill coefficient close to 1.7) and
a lack of end-product inhibition at physiological concentrations
of G6P. In addition, in contrast with the activity of the other
hexokinase isoforms, GK activity is regulated through protein–
protein interactions by the GKRP (GK regulatory protein), which
acts as a competitive inhibitor with respect to glucose and also
regulates the nucleocytoplasmic localization of the enzyme [3–5].
The correct functioning of GK in β-cells is essential for
maintaining glucose homoeostasis in the organism, and mutations
in the GCK gene may cause different monogenic glycaemic dis-
orders in humans [6]. In general terms, GK mutations that in-
crease GK activity produce hypoglycaemia due to congenital
hyperinsulinism, HI (hyperinsulinaemia of infancy) (OMIM
#601820; [7]). In contrast, GCK mutations that decrease enzyme
activity produce hypoinsulinism and hyperglycaemia. GCK-
inactivating mutations carried out in both alleles produce PNDM
(permanent neonatal diabetes mellitus) (OMIM #606176; [8])
and, in one allele, MODY (maturity-onset diabetes of the young)
type 2 (OMIM #125851 [9]). MODY is a form of diabetes mellitus
characterized by an onset that usually appears before 25 years of
age, often in childhood and adolescence, and abnormal β-cell
function and insulin secretion [10]. The MODY2 phenotype is
characterized by a mild form of hyperglycaemia present from
birth, but often asymptomatic and only detected later in life [11].
MODY2 patients are usually treated with diet alone and rarely
develop diabetic-associated complications [12].
Nearly 200 mutations spanning the complete GCK gene have
been described as being involved in GK-associated pathologies
(for a review, see [6]). These mutations, which are located along
the ten exons of the gene expressing the pancreatic β-cell isoform
of GK, include nonsense, missense and frameshift mutations
produced by deletions or insertions. However, only less than one-
fifth of these mutations have been functionally characterized [6].
The structural model and the crystal structure of human GK have
been determined in both its active liganded and inactive free forms
[13,14], and the functional characterization of naturally occurring
GCK missense mutations involved in glycaemic disorders has
provided further clues to the basic biochemistry and biophysics of
Abbreviations used: DTT, dithiothreitol; GK, glucokinase; GKRP, GK regulatory protein; GlcNAc, N-acetylglucosamine; G6P, glucose 6-phosphate; GST,
glutathione S-transferase; Ia, activity index; MH, mannoheptulose; MODY, maturity-onset diabetes of the young; OGTT, oral glucose tolerance test; SD
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this enzyme. These studies have contributed to a better knowledge
of the mechanisms by which GK acts as a glucose sensor and in-
tegrates blood glucose levels and insulin release. The GK-
activating mutations involved in hyperinsulinism increase sub-
strate affinity and are clustered at the allosteric site of the enzyme
[14]. In contrast, MODY2 mutations are located throughout the
gene, and most of them are inactivating mutations that affect one
or several kinetic parameters of the enzyme (decreased substrate
affinities, combined or not with reduced specific activity) [6].
These effects, which can be translated into a lower activity index,
lead to an increased threshold for glucose-stimulated insulin
release [15]. However, some GCK mutations found in MODY
families do not appear to affect the enzymatic activity of GK as
presumed. An example is the GCK mutation Val62 → Met, found
in two MODY2 families, which results in a kinetically activated
enzyme [16]. Its implication in MODY has been explained by
other mechanisms, such as protein instability and the loss of
regulation by associated proteins and allosteric activators.
In this study, we report the identification and functional analysis
of GCK missense mutations found in Spanish MODY families and
we show that they co-segregate with diabetes. These mutations in-
clude two novel GK mutations, Leu165 → Phe, which is located in
proximity to the active site, and Glu265 → Lys, which is located
in a more external position that is not physically associated with
the glucose-binding site, together with a third, Thr206 → Met,
that has been reported previously [17–20] but has not yet been
characterized biochemically. In the present study, we provide a
functional characterization of these mutations by measuring their
effect on the kinetic parameters of the enzyme, on protein stability
and on the interaction of GK with the GKRP. Our data indicate
that, whereas mutations Leu165 → Phe and Thr206 → Met affect the
catalytic activity of the enzyme directly, mutation Glu265 → Lys




The probands of families P5, P6 and P7 were referred to our lab-
oratory by P. B.-P., E. D.-A. and F. D.-C., and the one for
family P22 by S. A., for a molecular diagnosis of MODY. The
clinical diagnosis of MODY was made using the classical criteria:
impaired fasting glucose or development of diabetes before
age 25, negative search for the markers of Type I diabetes [ICA
(islet cell antibodies), GAD (glutamic acid decarboxylase anti-
bodies), IA2 (tyrosine phosphatase antibodies) and IAA (insulin
auto-antibodies)] and a family history of diabetes for at least two
consecutive generations. Informed consent was obtained from
the subjects or from their parents. The studies were performed
according to the Declaration of Helsinki and approved by the
corresponding ethical committees.
SSCP (single-strand conformation polymorphism) analysis
of the GCK gene
Genomic DNA was isolated from human leucocytes using
standard methods [21]. PCR of the ten exons of the GCK gene
expressed in β-cells (GenBank® accession number AH005826)
was accomplished using previously described primer sequences
[22]. SSCP analysis was performed with two electrophoretic
conditions, as described in [23]. Genomic DNA from patients
showing abnormal SSCP conformers were re-amplified and se-
quenced on a 3730 DNA analyser (Applied Biosystems) at the
sequencing facility of the Complutense University.
Production of recombinant wild-type and mutant GST (glutathione
S-transferase)–GK
The recombinant human wild-type β-cell GK fused to GST
(GST-GK) was prepared as described previously [5]. MODY-
associated mutations were introduced into the GST–GK construct
by PCR. To generate mutation Leu165 → Phe, two first PCR
fragments, A and B, were produced using primers hGK379,
5′-AGCAGATCCTGGCAGAGTTC-3′, and hGK827r, 5′-GTT-
GAAAAGGATCCCCTTATCGATGTCTTC-3′, for A, and
hGK798, 5′-GAAGACATCGATAAGGGGATCCTTTTCAAC-3′,
and hGK1222r, ATGTACTTGCCACCTATGAG-3′, for B. PCR
fragments A and B were used as a template in a new PCR
reaction with primers hGK379 and hGK1222r. The resulting
PCR fragment was digested with PstI and SacI, and was in-
troduced into the wild-type GST-GK construct by replacing the
wild-type fragment. Using the same method, mutation Thr206 →
Met was generated using primers hGK379 and hGK956r, 5′-CG-
TGGCCACCATGTCATTCACCATGGCCAC-3′, for A, and
hGK927, 5′-GTGGCCATGGTGAATGACATGGTGGCCACG-
3′, and hGK1222r for B. Finally, mutation Glu265 → Lys was gen-
erated similarly using primers hGK379 and hGK1142r, 5′-
CAGCAGGAACTCGTCAAGCTTGCCGGAGTC-3′, for A, and
hGK1113, 5′-GACTCCGGCAAGCTTGACGAGTTCCTGC-
TG-3′, and hGK1389r, 5′-TGCTCAGGATGTTGTAGATC-3′ for
B. Constructs carrying mutations Leu165 → Phe, Thr206 → Met
and Glu265 → Lys were checked by sequencing and digestion with
BamHI, NcoI and HindIII respectively. Escherichia coli BL21
strain was transformed with the indicated plasmids and grown
at 37 ◦C to mid-exponential phase. Expression of fusion proteins
was induced by adding IPTG (isopropyl β-D-thiogalactoside) to
a final concentration of 0.2 mM, and cultures were incubated
with orbital shaking for 16 h at 22 ◦C. GST–GK fusion proteins
were purified from crude E. coli extracts by single-step affinity
chromatography using glutathione–agarose (Sigma–Aldrich),
essentially as described in [24]. Briefly, 200 ml of bacterial
culture was pelleted and resuspended in 25 ml of 0.1 M PBS
containing 5 mM DTT (dithiothreitol). Cells were lysed by using
a French Pressure cell press (Thermo IEC) after adding Triton
X-100 to a final concentration of 1%. The supernatant of the
lysate was mixed with 50% glutathione–agarose beads, which
were collected by centrifugation at 500 g for 5 min before being
washed twice with the same buffer. Fusion proteins were eluted
with 50 mM Tris/HCl, pH 8.0, 200 mM KCl, 10 mM glutathione
and 5 mM DTT, and were stored at a concentration of approx.
1 mg/ml at −80 ◦C in 30% (v/v) glycerol, 50 mM glucose,
10 mM glutathione, 5 mM DTT, 200 mM KCl and 50 mM Tris/
HCl, pH 8.0, as indicated in [25]. Protein concentrations were
determined using the Bio-Rad protein assay kit with BSA as
standard. GST–GK purification resulted in a single band on
Coomassie-Blue-stained SDS/10% PAGE gels.
Kinetic parameters
GK activity was measured spectrophotometrically on a Kontron
930 spectrophotometer, using an NADP+-coupled assay with glu-
cose-6-phosphate dehydrogenase, as described in [26], with the
modifications introduced in [24]. One unit of GK is defined as
the amount of enzyme that phosphorylates 1 µmol of glucose
per min at 30 ◦C. In order to determine the kinetic variables for
glucose, 15 different concentrations of the substrate were used
(0.1–200 mM) with 5 mM ATP plus 1 mM MgCl2 in excess.
For the second substrate, ATP, nine different concentrations were
used (0.02–5 mM) with 100 mM glucose or with the correspond-
ing glucose concentration (S0.5), as indicated in the Results
section.
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Table 1 Phenotypic characteristics of index patients at the actual age
BMI, body mass index (normal range, 19–25 kg/m2; overweight, 25–30 kg/m2); FPG, fasting plasma glucose (normal range, 4.0–6.1 mM); OGTT, plasma glucose at 120 min after a 75 g
OGTT; HbA1c (normal range, 4.0–5.2 %); basal C-peptide (normal range, 1–4 nM); M, mother; F, father; B, brother; S, sister; Sn, son; pA, paternal aunt; pU, paternal uncle; pGF/pGM, paternal
grandfather/grandmother. N.A., not analysed. Underlined are those affected family members where mutation was checked by genotyping.
Family Age at diagnosis (years) Age now (years) Patient sex BMI (kg/m2) FPG (mM) OGTT (mM) HbA1c (%) Basal C-peptide (nM) Affected family members
P5 23 33 Male 26 7.1 6.4 6.3 1.5 M, B
P6 20 50 Male 30 6.6 11.4 6.7 3.5 M, B, two Sn
P7 20 32 Female 21 6.8 12.2 6.2 2.1 pGF, F
P22 14 34 Female 19 8.0 N.A. 6.5 1.2 pGM, F, pA, two pU, S
The Hanes–Woolf plot was used to calculate the GK Vmax
and the Km values for ATP. The Hill plot was applied to esti-
mate the Hill coefficient of GK towards glucose and the S0.5 for
this substrate. The concentration of glucose at which the inflection
point occurs was calculated as indicated in [25]. The kcat was
calculated as Vmax/mol of GK using glucose as variable substrate.
To give kcat values, the results were extrapolated to 37 ◦C, as
indicated in [15,27]. The activity index (Ia), derived from the
kinetic variables, kcat, S0.5, h, ATP concentration and the Km for
ATP, was calculated as indicated in [15]. The sensitivity of wild-
type and mutant GK to inhibition by competitive inhibitors was
determined at a glucose concentration close to the S0.5 value or
below. IC50 values were derived from Dixon plots [28], using
three concentrations of glucose (3, 5 and 7.5 mM for the wild-type
protein, and 25, 50 and 75 mM or 7.5, 10 and 15 mM for proteins
carrying mutations Leu165 → Phe and Glu265 → Lys respectively),
and five concentrations of inhibitors [0.05–1 mM for GlcNAc (N-
acetylglucosamine) and 0.5–10 mM for MH (mannoheptulose)].
Thermal stability tests were performed as in [25]. Results are
shown as the means +− S.E.M., and statistical significance was
analysed by the unpaired Student’s t test. P values of <0.01 were
considered to be statistically significant.
Yeast two-hybrid protein–protein interaction test
The Saccharomyces cerevisiae strain used for two-hybrid studies
was Y187 (MATα, ura3-52, his3-200, ade2-101, trp1-901, leu2-
3,112, gal4∆, met−, gal80∆, URA3::GAL1UAS-GAL1TATA-LacZ;
Clontech). Standard genetic methods were used. Yeast cells
were grown in SD (synthetic dextrose minimal) medium lacking
appropriate supplements to maintain selection for plasmids [29].
For β-galactosidase assays, transformants were patched on to
selective SD medium and were grown for 2 days at 30 ◦C. Filter
lift assays for blue colour were performed as described previously
[30] and developed for 1 h. A plasmid encoding a GKRP fusion
protein to the Gal4-binding domain was constructed by inserting
a BamHI/XhoI fragment from pGEX-5X-2-GKRP [5] containing
the GKRP coding sequence between the BamHI and SalI sites
of the polylinker of pGBKT7 (Clontech). A construct encoding a
fusion of GK and mutant derivatives to the Gal4-activating domain
was derived from pACTII (Clontech) by inserting a BamHI/XhoI
fragment from the respective GST–GK constructs containing the
GK coding sequence between the BamHI and XhoI sites of
the polylinker.
RESULTS
Clinical features of the patients
All the patients studied as probands for genetic diagnosis of
MODY2 had a clinical history of at least two consecutive gene-
Table 2 GCK mutations in MODY families
Nucleotide numbering uses +1 as the adenine of the ATG initiation codon, based on the
GenBank® sequence AF041021. Novel mutations are indicated in bold.
Family Gene exon Nucleotide change Amino acid change
P6 GCK 5 c.493C > T Leu165→ Phe
P5 GCK 6 c.617C > T Thr206 → Met
P7 GCK 6 c.617C > T Thr206 → Met
P22 GCK 7 c.793G > A Glu265→ Lys
rations and age of diagnosis below 25 (Table 1). These patients had
fasting hyperglycaemia values ranging from 6.6 to 8.0 mM, which
are in the normal range for MODY2 patients [6]. The OGTT (oral
glucose tolerance test) in families P6 and P7 gave increment values
above 3 mM, which is the average found in MODY2 families [31].
HbA1c values were above the normal range, and fasting serum C-
peptide levels were normal. Probands of families P5 and P6 were
overweight. All of these patients were treated with diet alone and
did not show any chronic diabetic complications.
Identification of novel missense mutations in the GCK gene
The ten exons of the GCK gene expressed in β-cells were scanned
for mutations using SSCP on the probands from each of the
affected families. Sequencing of abnormal migrating bands
revealed the heterozygous mutations shown in Table 2. The
novel missense mutations in GCK exon 5 of family P6 (codon
165 CTC → TTC) and exon 7 of family P22 (codon 265
GAG → AAG) result in the GK mutations Leu165 → Phe and
Glu265 → Lys respectively. In addition, the apparently unrelated
families P5 and P7 showed the same mutation in exon 6 (codon
206 ACG → ATG), resulting in GK mutation Thr206 → Met. The
presence of this last mutation has also been reported in three
unrelated Italian families [17–19] and one German family [20].
These mutations co-segregate with the MODY phenotype in
the available individuals in their respective families (Table 1).
Moreover, the novel missense mutations in codons 165 and
265 were not found in 55 unrelated healthy individuals used as
controls, who showed normal conformers of SSCP as compared
to the probands and their affected relatives (results not shown).
Based on the model of the protein structure of GK [13,14],
Thr206 and Leu165 are located in the substrate-binding cleft or very
close to the active site (Figure 1A). Glu265 is located on a more
external position of the enzyme and not in the immediate vicinity
of the substrate-binding site (Figure 1A). On the other hand, as
shown in Figure 1(B), Leu165 and Thr206 are highly conserved
among GKs and hexokinases, and Glu265 is only conserved among
GKs.
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Figure 1 Localization of the mutated residues Leu165, Thr206 and Glu265 on the structural model for the β-cell GK and multiple sequences alignment of GKs
and hexokinases from different species at the positions where mutations were identified
(A) Closed conformation (PDB code 1V4S) of wild-type GK [14] is represented using the RasMol program [48]. Mutated residues in the MODY families are indicated as black sticks and ribbons.
The position of glucose is indicated as a black sphere. (B) Alignment of human (Hum) GK (GenBank® accession number NP 277042), mouse liver GK (GenBank® accession number NP 034422),
rat liver GK (GenBank® accession number NP 036697), Xenopus (Xen) liver GK (GenBank® accession number X93494), rat hexokinase I (GenBank® accession number NP 036866) and rat
hexokinase II (GenBank® accession number NP 036867) using the ClustalW program. Numbers indicate amino acid positions in the proteins. Boxes indicate the conservation of the corresponding
residues.
Table 3 Kinetic constants of human recombinant wild-type and MODY2 mutant β-cell GST–GK fusion proteins
Results are means +− S.E.M. of n separate enzyme expressions. IC50 was measured in three separate enzyme expressions of each mutant. Note that the Hill coefficient (h) and the relative activity
index (Ia) are unitless. *P < 0.01; **P < 0.001.
Protein yield Kcat S0.5 for glucose Inflection point K m for ATP IC50 GlcNAc IC50 MH
Preparation (mg/l) (s−1) (mmol/l) h (mmol/l) (mmol/l) Ia (mmol/l) (mmol/l)
Wild-type GST–GK 9.2 +− 2.8 42.0 +− 7.0 8.0 +− 0.2 1.53 +− 0.02 2.8 +− 0.13 0.4 +− 0.04 1 0.25 +− 0.03 1.16 +− 0.14
(n = 6)
GST–GK(L165F) 14.0 +− 3.6 18.0 +− 4.0* 92.5 +− 9.5** 1.21 +− 0.03** 12.2 +− 1.5* 1.52 +− 0.08** 0.034 +− 0.009* 0.62 +− 0.06* 6.5 +− 0.17**
(n = 5)
GST–GK(T206M) 13.0 +− 3.9 0.18 +− 0.14** 85.0 +− 27* 0.90 +− 0.03** – 0.45 +− 0.13 0.002 +− 0.001*
(n = 3)
GST–GK(E265K) 3.5 +− 0.5b 36.8 +− 7.9 15.5 +− 1.3* 1.43 +− 0.04 4.7 +− 0.6 0.63 +− 0.02* 0.4 +− 0.1* 0.20 +− 0.02 1.05 +− 0.05
(n = 6)
Biochemical characterization of recombinant mutant GKs
In order to investigate the effect of the GK mutations Leu165 →
Phe, Thr206 → Met and Glu265 → Lys on GK activity, we
bacterially expressed recombinant wild-type and mutant GKs
as GST-fusion proteins [GST–GK, GST–GK(L165F), GST–
GK(T206M) and GST–GK(E265K) respectively]. The strategy
in which GK is expressed fused to GST allows the purification of
the fusion protein in a single-step procedure [24], and has been
used extensively by researchers to study GK mutations, also being
recognized as advantageous for the analysis of labile mutants
[15,16,25]. Six preparations of wild-type GK and at least three
of each mutant derivative were purified, with yields ranging from
3.5 to 14 mg/l (Table 3), the lowest value being obtained for the
mutant GST–GK(E265K). The purity of each purified GST–GK
protein was analysed by SDS/10% PAGE and Coomassie Blue
staining. In all cases, a single band of 75 kDa was detected (results
not shown).
The kinetic behaviour of GK with its main substrate, glucose,
is represented in Figure 2. The values for the kinetic variables,
including the catalytic constant, kcat, and substrate affinities (S0.5
for glucose and Km for ATP) are shown in Table 3. The strongest
effect on GK activity was observed for mutation Thr206 → Met,
with an activity index corresponding to 0.2% of the wild-type GK
activity index. Data analysis for this mutant was somehow limited,
since the specific activity was very low, despite good protein
yields, and the kinetic results are therefore approximations. This
mutant displayed a >10-fold lower affinity for glucose than the
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Figure 2 Glucose-dependent activity of the mutated forms of GK
Specific activity at each glucose concentration was calculated as described in the Experimental
section. Results are means +− S.E.M. for n separate enzyme expressions.
wild-type protein and might have lost the co-operativity for this
substrate, as shown by an approximate Hill coefficient close to
1. In contrast, the affinity for the second substrate ATP did not
appear to be affected. The activity index of the mutant GK carrying
mutation Leu165 → Phe was approx. 4% of that of the wild-type
GK. The catalytic constant of this mutant was reduced to one-
half of the wild-type value, and the affinities for both substrates
(glucose and ATP) were almost 12- and 4-fold lower respectively.
Mutation Glu265 → Lys elicited the weakest kinetic effect and the
activity index was only reduced to 40% of the wild-type GK ac-
tivity index. This effect is mainly due to a decrease in the affinity
for glucose and a slight decrease in affinity for ATP, since the kcat
remained almost unaffected.
Because all three mutations had an effect on the affinity for
glucose, we tested the inhibitory effect of two well-known GK
competitive inhibitors, namely GlcNAc and MH. In order to
measure the affinity values for these effectors independently of
the effect of the mutations on glucose affinity, the wild-type
GST–GK and mutant derivatives were tested at a maximum
substrate concentration corresponding to their respective S0.5
values (see the Experimental section). As shown in Table 3,
mutation Leu165 → Phe conferred a significantly lower sensitivity
to both the GK competitive inhibitors MH and GlcNAc. In
contrast, mutation Glu265 → Lys had no effect on the affinity of
GK for these compounds.
It has been described previously that certain MODY2 mutations
affect GK protein stability and/or regulation by the GKRP pro-
tein [16,25]. The effect of the Leu165 → Phe, Thr206 → Met
and Glu265 → Lys mutations on the protein–protein interaction
between GK and GKRP was tested in the two-hybrid system in
yeast. This method has been extensively used to analyse mam-
malian protein–protein interactions [32]. All three mutations do
not appear to affect the interaction of GK with GKRP in two-
hybrid assays (Figure 3). The protein stability of wild-type
GST–GK and mutant derivatives was tested at different
temperatures. As described previously [25], GK activity remained
practically constant under a temperature increase of up to 50 ◦C,
but enzymatic activity fell abruptly at 52 ◦C (Figure 4A). Both
Figure 3 Two-hybrid interaction between GK and mutant derivatives and
the GKRP
Two-hybrid interaction of Gal4-binding domain–GRKP with Gal4-activating domain–GK and its
mutant derivatives were tested in S. cerevisiae strain Y187. Filter lift assays were developed for
1 h. In each case, three independent transformants were tested, with similar results.
Figure 4 Effects of temperature on the stability of GST–GK variants
Stock enzyme solutions were diluted to 250 µg/ml in storage buffer containing 30 % (v/v)
glycerol, 50 mM glucose, 10 mM glutathione, 5 mM DTT, 200 mM KCl and 50 mM Tris/HCl,
pH 8.0. (A) The enzyme solutions were incubated for 30 min at different temperatures ranging
from 30 to 55◦C and then assayed at 30◦C as described in the Experimental section.
(B) The enzyme solutions were incubated for different periods of time from 5 to 60 min at
50◦C. Means +− S.E.M. for three independent enzyme preparations are shown for each case.
mutations Leu165 → Phe and Glu265 → Lys conferred thermal
instability, since the enzymatic activity of the corresponding
mutant proteins was decreased at 50 or 52 ◦C, as compared with
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the wild-type. The time-course analysis of thermal inactivation
shown in Figure 4(B) indicates that mutation Glu265 → Lys
produces the strongest effect on protein stability and that 80% of
GK activity is lost within the first 10 min of incubation at 50 ◦C.
Interestingly, although mutation Leu165 → Phe produced a
50% decrease in GK activity after 10 min at 50 ◦C, the residual
activity remained constant over the ensuing 30 min at the same
temperature, but decreased to 20% of the wild-type value after
60 min of incubation.
DISCUSSION
In the present study, we have identified two novel GCK mutations,
resulting in GK mutations Leu165 → Phe and Glu265 → Lys, in
Spanish MODY families and have shown that these mutations
co-segregate with diabetes in their respective families and are
not found in over 100 chromosomes from non-diabetic control
subjects. We completed this molecular diagnosis by a functional
analysis of the molecular effects of these mutations on GK
enzymatic activity, protein stability and interaction with the
GKRP protein. Moreover, we report another missense mutation,
Thr206 → Met, identified previously in other MODY families. The
presence of this missense mutation in two of our families
prompted us to include it in the functional study carried out for
the novel mutations.
The functional characterization of GK mutations Leu165 → Phe,
Thr206 → Met and Glu265 → Lys, revealed that the corresponding
residues are important for GK activity. As seen for most of the
MODY2 mutations, these mutations are kinetically inactivating
and affect one or more kinetic parameters and, in some cases,
also protein stability. We found a good correlation between
the structural localization of the mutated residue and the effect
on enzymatic activity. The recently defined crystal structure of
human GK indicates that this protein has a large and a small
domain, separated by a deep cleft [14]. Glucose binds to the
interdomain cleft, composed of residues of the large domain
(Glu256 and Glu290), the small domain (Thr168 and Lys169) and
the connecting region I (Asn204 and Asp205). Upon binding to
substrates (glucose and ATP), GK undergoes a conformational
change that brings the large and the small domains physically
closer, resulting in a closed active conformation. Residue Thr206
is located in the α5 helix, inside the hinge of the active site,
corresponding to the glucose-binding site [13]. The importance
of the α5 helix for GK function has been demonstrated [14,33].
The effect of substitution of methionine for Thr206 is devastating
since the enzyme was inactivated by more than 99%. Although
our results are only approximations due to the poor activity of this
GK mutant, they suggest that this mutation has a strong effect on
the affinity for glucose, but apparently not on the affinity for
ATP. Although there are no ‘hot spot’ mutations in the GCK
gene, nearly 50 mutations have been identified in more than
one family [6]. In particular, mutation Thr206 → Met has been
reported in five unrelated families, including the two described
here, and a mutation in the same nucleotide position, which
produces a Thr206 → Arg mutation, has also been identified in
another MODY2 family [34]. Finally, a randomly generated
Thr206 → Met mutation associated with hyperglycaemia has been
obtained in a mouse model by using the chemical mutagen N-
ethyl-N-nitrosourea [35].
The novel mutation Leu165 → Phe is a substitution of phenyl-
alanine, which is an aromatic and bulky residue, for a leucine
residue that is located very close to the active site. This mutation
affects the enzyme affinity for both substrates (glucose and
ATP), although the strongest effect is observed on the S0.5 for
glucose. It also affects enzyme co-operativity and decreases the
affinity for the glucose competitive inhibitors MH and GlcNAc.
In addition, we found that the mutant protein GST–GK(L165F) is
thermally unstable in vitro. Since glucose has a dramatic effect on
GK stability, the relative instability of GST–GK(L165F) could
be a consequence of its poor affinity for glucose, mitigating
the physiological protection of the enzyme by its substrate, as
postulated for other MODY2 mutations [25]. This effect could
explain why only a fraction of the enzyme appears to be unstable
shortly after a shift to 50 ◦C, in our time-course experiments.
Leu165 is located on the β7 strand in the GK structure. The
predictable involvement of this region of the protein in the active
site of the enzyme (Figure 1A) is supported further by the results
of a site-directed mutagenesis of the neighbouring GK residue
Asn166 to an arginine residue. The Asn166 → Arg mutation also
affects the affinity of GK for glucose, although with the opposite
effect, and decreases the enzyme co-operativity (a similar low Hill
coefficient as for Leu165 → Phe) [36].
In family P22 reported in the present paper, Glu265 is changed
to a lysine residue to afford the novel mutation Glu265 → Lys.
Glu265 is located in a region of the protein between the β11
strand and the α6 helix. From the structural model, it could not be
anticipated whether this glutamic acid residue participates directly
in the interaction of the active site with the substrates glucose and
ATP [14,37]. Although the kinetic analysis indicates that this
substitution has a small, but significant, effect on the affinity for
both substrates, it does not appear to affect the sensitivity of GK
to competitive inhibitors, suggesting that Glu265 would not be
involved directly in the active site of the enzyme. In contrast,
we found a strong effect of mutation Glu265 → Lys on protein
stability. The change Glu265 → Lys corresponds to a substitution
of a positively charged amino acid for a negatively charged one.
This critical change in polarity might impair the folding of the
enzyme during biosynthesis in vivo, as proposed for another
MODY2 mutation that involves a similar amino acid substitution
(Glu300 → Lys; [25,38]). Both the Glu300 → Lys and Glu265 → Lys
mutant proteins are expressed at low levels in E. coli, which could
be a result of their instability. The apparent thermal instability
of these mutant proteins should be considered as a factor that
might decrease the Ia of the enzyme further as compared with
that of the wild-type. Alternatively, we cannot rule out a possible
involvement of Glu265 in a specific function of GK, not related
directly to the active site of the enzyme. Interestingly, this residue
is only conserved among GKs, but not hexokinases. In addition,
a MODY2 mutation that involves the contiguous amino acid
(Gly264 → Ser) has no effect on enzyme kinetics [39]. We explored
the possible involvement of Glu265 in the interaction with GKRP.
However, none of the three missense mutations studied appeared
to affect this interaction in the yeast two-hybrid system. We cannot
discard the possibility that the Glu265 → Lys mutation might affect
the association of GK with other known GK partners, such
as the bifunctional enzyme 6-phosphofructo-2-kinase/fructose-
2,6-bisphosphatase [40,41], the dual-specific phosphatase [42] or
the neuronal nitric oxide synthase [43].
Most of the patients from the different families studied had
relatively mild basal levels of fasting hyperglycaemia even 10–
30 years after clinical diagnosis, and were being treated with diet
alone. Despite the differences in the effects of these mutations
on the kinetic parameters of GK, fasting plasma glucose levels
did not differ very much in the different families and all of them
were within the average (6–8 mM) described for MODY patients
carrying GCK mutations [6]. Based on the mathematical model
proposed by Matschinsky’s group [15], there is good evidence
that any decrease in the Ia below 30% of the wild-type value
would have little further effect on the fasting plasma glucose
c© 2006 Biochemical Society
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levels. Interestingly, the increment of plasma glucose levels after
OGTT for probands P5 (−0.7 mM) and P7 (+5.4 mM) differed
from each other, despite these probands carrying the same GK
mutation Thr206 → Met. Such a difference can also be observed
with patients carrying the same mutation, described in previous
studies {(+0.2 mM) [20] and (+4.7 mM) [18]}. These results
are in agreement with the fact that genetic background and/or life
style of the individuals affect the phenotypic characteristics of the
MODY2 mutations.
Despite the fact that a large number of GCK mutations asso-
ciated with MODY2 have been reported previously, in most
countries, including Spain, new cases are still emerging from
molecular diagnosis [44,45]. The importance of performing a mol-
ecular diagnosis of MODY has already been discussed in depth
and emphasized by the clinical and scientific community owing
to the implications for clinical management. Furthermore, the
functional analysis of novel GK mutations provides new clues to
the mechanisms involved in the regulation of GK activity. The
importance of these studies for the development of new diabetic
therapies is emphasized further by the recent discovery of small
drugs acting as allosteric activators of GK which are able to
increase GK activity in vitro and in normal and diabetic animal
models [46,47].
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